The expansion of the "Medical Headline Jun" electronic health card and the breakthrough of the three medical associations

(2020/11/19) Gilead's new shell functional inhibitor lenspavir Phase 2/3 clinical end point; iNKT cell therapy "recruiter" - dual-specific antibodies; layout acceleration! A brief analysis of the current situation and trends of gene therapy industry in China... (Click on the title to get the original text) "Pharmaceutical 1st Time" Gilead's new shell function inhibitor lenspavir Phase 2/3 clinical reached the main end! On November 18, Gilead announced the top-line results of the Phase 2/3 clinical CAPELLA trial, which evaluated the efficacy and safety of the research-based, long-acting HIV-1 shell inhibitor lensavivir, which has been treated multiple times for HIV Type 1 (HIV-1) multiple drug-resistant infections.
: The drug could be the first HIV shell inhibitor to be used to treat HIV-1 infections.
"Arterial Network" electronic health card expansion and the three doctors linked to the break "first chicken, or first have eggs?" "This is a philosophical question of exploring the origin of life, but it also appears on the exploration of electronic health cards.
, the electronic health card is "chicken" and the application behind it is "egg".
: It's hard to realize the dream from "healthy China Chinese "healthy and healthy".
Medical Rubik's Cube iNKT cell therapy "recruiter" - dual-specific antibody constant natural killer T cells is a congenital CD1d restricted T cells, expressing constant T-cells in the thymus through a unique differentiation process, obtaining NK-like characteristics, including strong cytotoxicity, rapid secretion of cytokines, can be effectively transported to the tissue medium.
unlike NK cells, target recognition of NKT cells is limited by CD1d (the interaction of NKT cells with glycolipids presented by CD1d), similar to T cell recognition targets are limited by HLA.
: Iso-iNKT cell therapy is moving towards clinical development.
the "Firestone Creation" layout acceleration! China's gene therapy industry status quo and trends of gene therapy industry or will become antibody drugs after the future of the biopharmaceutical industry key development direction, China's industrial innovation activity has been increasing, supporting the service system is constantly improving, but at the same time the upstream industrial chain core link card neck phenomenon is still serious, need to break through.
: Capital support, government policies will enter deep water for cell/gene therapy.